Cargando…

Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma

Herein we report the impact of localized delivery of an anti-mouse PD-1-specific monoclonal antibody (aPD1) on Renca tumors in the resulting T cell responses and changes in broader immune gene expression profiles. Renca is a BALB/c mice syngeneic tumor that has been used to model human renal cell ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, Ngoc B., Abraham, Nevil, Velankar, Ketki Y., Schueller, Nathan R., Philip, Errol J., Jaber, Yasmeen, Gawalt, Ellen S., Fan, Yong, Pal, Sumanta K., Meng, Wilson S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486680/ https://www.ncbi.nlm.nih.gov/pubmed/36132332 http://dx.doi.org/10.3389/fddev.2022.838458

Ejemplares similares

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices
por: Salgia, Nicholas J., et al.
Publicado: (2020)

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities
por: Castro, Daniela V., et al.
Publicado: (2022)

Antimicrobial Activity of Nitric Oxide-Releasing Ti-6Al-4V Metal Oxide
por: Reger, Nina A., et al.
Publicado: (2017)

Effect of Alkyl Chain Length on Carboxylic Acid SAMs on Ti-6Al-4V
por: Buckholtz, Gavin A., et al.
Publicado: (2012)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Esfahani, Khashayar, et al.
Publicado: (2019)

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
por: Zhu, Jason, et al.
Publicado: (2018)

Combination CD200R/PD-1 blockade in a humanised mouse model
por: Fellermeyer, Martin, et al.
Publicado: (2023)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation
por: Liu, Shin-Yi, et al.
Publicado: (2019)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma
por: Ran, Xia, et al.
Publicado: (2020)

Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
por: Waaler, Jo, et al.
Publicado: (2020)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy
por: Jahangir, Mohammadsaleh, et al.
Publicado: (2022)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse
por: Huard, Bertrand, et al.
Publicado: (2012)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017)

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
por: Li, Yuan, et al.
Publicado: (2018)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
por: GE, WENFEI, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
por: Rosenzweig, Neta, et al.
Publicado: (2019)

T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy
por: Bruns, Michael, et al.
Publicado: (2016)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Recent advances and application of PD-1 blockade in sarcoma
por: Zuo, Wenli, et al.
Publicado: (2019)

Is PD-1 blockade a potential therapy for HBV?
por: Féray, Cyrille, et al.
Publicado: (2019)

Optimum fractionation of radiation to combine PD‐1 blockade
por: Teng, Feifei, et al.
Publicado: (2023)

CORRECTION NOTICE “Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma”
Publicado: (2022)

Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
por: Li, Le, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7uf5meb6de7m53g1t6nl179o5